Close this window to return to IVIS
www.ivis.org

# Proceedings of the European Veterinary Conference Voorjaarsdagen

The Hague, the Netherlands
Apr. 13-15, 2016

Next Meeting:

April 19-21, 2017
The Hague, The Netherlands

Reprinted in IVIS with the permission of the Conference Organizers
http://www.ivis.org

Reprinted in IVIS with the permission of the Organizers

Close window to return to IVIS





# EFFICACY OF AMITRAZ PLUS INACTIVATED PARAPOXVIRUS OVIS IN THE TREATMENT OF CANINE GENERALISED DEMODICOSIS

Didem Pekmezci, Assoc. Prof., DVM, Ph.D.;
Zafer Pekmezci, Assoc. Prof., DVM, Ph.D.;
Murat Guzel, Prof., DVM, Ph.D.;
Sena Cenesiz, Prof., DVM, Ph.D.;
Tumay Gurler, Assoc. Prof., DVM, Ph.D.;
Guvenc Gokalp, DVM, Ph.D.

Department of Internal Medicine, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun 55139 Turkey

dkazanci@omu.edu.tr

Canine generalized demodicosis (CGD) is a challenging disease to treat effectively. Inactivated parapoxvirus ovis (iPPVO) could help to accelerate treatment with acaricidial therapy by altering the immune response. This study was designed to investigate the effects of treating CGD with amitraz plus iPPVO in terms of clinical outcomes and blood parameters. The study involved 16 dogs ranging in age from eight months to six years and weighing between 10 and 40 kg. Eight dogs were treated with amitraz and eight with amitraz plus iPPVO. Biochemical analysis of whole blood and serum, including serum C reactive protein (CRP) and serum amyloid A (SAA), was performed. Skin scrapings were conducted on days 0, 10, 40, 80 and 120 of treatment, and mite numbers were recorded. Clinical remission was determined according to mite numbers and clinical scores. The difference in mean whole remission days between the amitraz group (104.3 days) and the amitraz+iPPVO group (84.5 days) was statistically significant ($P<0.05$). Mean clinical scores were also significantly better in the amitraz+İPPVO (5.60) group when compared with the amitraz group (7.65). No adverse reactions were observed in either group. In view of these findings, the use of iPPVO in conjunction with amitraz can be recommended for treating CGD.